Patents by Inventor Li-Fen Lee

Li-Fen Lee has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • ANTI-B7-H4 CONSTRUCTS AND USES THEREOF
    Publication number: 20230112085
    Abstract: The present application provides anti-B7-H4 constructs that bind to B7-H4 (e.g., anti-B7-H4 antibodies), nucleic acid molecules encoding an amino acid sequence of the anti-B7-H4, vectors comprising the nucleic acid molecules, host cells containing the vectors, methods of preparing the anti-B7-H4 construct, pharmaceutical compositions containing the anti-B7-H4 construct, and methods of using the anti-B7-H4 construct or compositions.
    Type: Application
    Filed: January 29, 2021
    Publication date: April 13, 2023
    Inventors: Li-Fen LEE, Kan LU, Jessica YU, Sheng-Tien LI, Julie HUANG
  • METHODS AND COMPOSITIONS FOR TREATING CANCER OR VIRAL INFECTION WITH A PLA2G2D ANTAGONIST
    Publication number: 20230075779
    Abstract: The present application provides methods of treating a disease (such as cancer or infectious disease) that involves an antagonist that targets PLA2G2D signaling pathway (such as an antagonist that targets PLA2G2D. The present application also provides non-naturally occurring PLA2G2D polypeptides.
    Type: Application
    Filed: January 29, 2021
    Publication date: March 9, 2023
    Applicant: Apeximmune Therapeutics Inc.
    Inventors: Li-Fen LEE, Kan LU, Jessica YU, Sheng-Tien LI, Julie HUANG, Katharine YU
  • ANTAGONIST ANTI-IL-7 RECEPTOR ANTIBODIES AND METHODS
    Publication number: 20180327503
    Abstract: The present invention provides antagonizing antibodies that bind to interleukin-7 receptor (IL-7R). The invention further provides a method of obtaining such antibodies and antibody-encoding nucleic acids. The invention further relates to therapeutic methods for use of these antibodies and antigen-binding portions thereof for the treatment and/or prevention of type 2 diabetes and immunological disorders, including type 1 diabetes, multiple sclerosis, rheumatoid arthritis, graft-versus-host disease, and lupus.
    Type: Application
    Filed: July 20, 2018
    Publication date: November 15, 2018
    Applicant: RINAT NEUROSCIENCE CORP.
    Inventors: CHIA-YANG LIN, LI-FEN LEE, WENWU ZHAI
  • Antagonist anti-IL-7 receptor antibodies and methods
    Patent number: 10059772
    Abstract: The present invention provides antagonizing antibodies that bind to interleukin-7 receptor (IL-7R). The invention further provides a method of obtaining such antibodies and antibody-encoding nucleic acids. The invention further relates to therapeutic methods for use of these antibodies and antigen-binding portions thereof for the treatment and/or prevention of type 2 diabetes and immunological disorders, including type 1 diabetes, multiple sclerosis, rheumatoid arthritis, graft-versus-host disease, and lupus.
    Type: Grant
    Filed: April 22, 2016
    Date of Patent: August 28, 2018
    Assignee: RINAT NEUROSCIENCE CORP.
    Inventors: Chia-Yang Lin, Li-Fen Lee, Wenwu Zhai
  • ANTAGONIST ANTI-IL-7 RECEPTOR ANTIBODIES AND METHODS
    Publication number: 20160229917
    Abstract: The present invention provides antagonizing antibodies that bind to interleukin-7 receptor (IL-7R). The invention further provides a method of obtaining such antibodies and antibody-encoding nucleic acids. The invention further relates to therapeutic methods for use of these antibodies and antigen-binding portions thereof for the treatment and/or prevention of type 2 diabetes and immunological disorders, including type 1 diabetes, multiple sclerosis, rheumatoid arthritis, graft-versus-host disease, and lupus.
    Type: Application
    Filed: April 22, 2016
    Publication date: August 11, 2016
    Applicant: RINAT NEUROSCIENCE CORP.
    Inventors: CHIA-YANG LIN, LI-FEN LEE, WENWU ZHAI
  • Method of treating type 1 diabetes with antagonist IL-7 receptor antibodies
    Patent number: 9346885
    Abstract: The present invention provides antagonizing antibodies that bind to interleukin-7 receptor (IL-7R). The invention further provides a method of obtaining such antibodies and antibody-encoding nucleic acids. The invention further relates to therapeutic methods for use of these antibodies and antigen-binding portions thereof for the treatment and/or prevention of type 2 diabetes and immunological disorders, including type 1 diabetes, multiple sclerosis, rheumatoid arthritis, graft-versus-host disease, and lupus.
    Type: Grant
    Filed: December 17, 2013
    Date of Patent: May 24, 2016
    Assignee: Rinat Neuroscience Corp.
    Inventors: Chia-Yang Lin, Li-Fen Lee, Wenwu Zhai
  • ANTAGONIST ANTI-IL-7 RECEPTOR ANTIBODIES AND METHODS
    Publication number: 20140141018
    Abstract: The present invention provides antagonizing antibodies that bind to interleukin-7 receptor (IL-7R). The invention further provides a method of obtaining such antibodies and antibody-encoding nucleic acids. The invention further relates to therapeutic methods for use of these antibodies and antigen-binding portions thereof for the treatment and/or prevention of type 2 diabetes and immunological disorders, including type 1 diabetes, multiple sclerosis, rheumatoid arthritis, graft-versus-host disease, and lupus.
    Type: Application
    Filed: December 17, 2013
    Publication date: May 22, 2014
    Applicant: Rinat Neuroscience Corp.
    Inventors: Chia-Yang LIN, Li-Fen LEE, Wenwu ZHAI
  • Nucleic acid encoding IL-7 receptor alpha antibody
    Patent number: 8637273
    Abstract: The present invention provides antagonizing antibodies that bind to interleukin-7 receptor (IL-7R). The invention further provides a method of obtaining such antibodies and antibody-encoding nucleic acids. The invention further relates to therapeutic methods for use of these antibodies and antigen-binding portions thereof for the treatment and/or prevention of type 2 diabetes and immunological disorders, including type 1 diabetes, multiple sclerosis, rheumatoid arthritis, graft-versus-host disease, and lupus.
    Type: Grant
    Filed: September 26, 2012
    Date of Patent: January 28, 2014
    Assignee: Rinat Neuroscience Corp.
    Inventors: Chia-Yang Lin, Li-Fen Lee, Wenwu Zhai
  • Anti-IL-7 receptor antibodies
    Patent number: 8298535
    Abstract: The present invention provides antagonizing antibodies that bind to interleukin-7 receptor (IL-7R). The invention further provides a method of obtaining such antibodies and antibody-encoding nucleic acids. The invention further relates to therapeutic methods for use of these antibodies and antigen-binding portions thereof for the treatment and/or prevention of type 2 diabetes and immunological disorders, including type 1 diabetes, multiple sclerosis, rheumatoid arthritis, graft-versus-host disease, and lupus.
    Type: Grant
    Filed: February 23, 2011
    Date of Patent: October 30, 2012
    Assignee: Rinat Neuroscience Corp.
    Inventors: Chia-Yang Lin, Li-Fen Lee, Wenwu Zhai
  • ANTAGONIST ANTI-IL-7 RECEPTOR ANTIBODIES AND METHODS
    Publication number: 20110206698
    Abstract: The present invention provides antagonizing antibodies that bind to interleukin-7 receptor (IL-7R). The invention further provides a method of obtaining such antibodies and antibody-encoding nucleic acids. The invention further relates to therapeutic methods for use of these antibodies and antigen-binding portions thereof for the treatment and/or prevention of type 2 diabetes and immunological disorders, including type 1 diabetes, multiple sclerosis, rheumatoid arthritis, graft-versus-host disease, and lupus.
    Type: Application
    Filed: February 23, 2011
    Publication date: August 25, 2011
    Inventors: Chia-Yang Lin, Li-Fen Lee, Wenwu Zhai